Interventional Glaucoma

What do ophthalmologists consider the key advancements in treating glaucoma over the last several decades?

Emerging technologies, such as remote tonometry and genetic risk scoring, are revolutionizing glaucoma care by enabling earlier detection, personalized management, and more efficient use of resources.

We asked ophthalmologists what stands out to them in the history of treating glaucoma and where future treatments might be heading.

The procedure offers a renewed approach to suprachoroidal drainage, with potential for both combined and standalone glaucoma surgery.

The Elios procedure increased aqueous humor outflow in all investigated eyes, but further studies are needed to correlate these improvements with its clinical efficacy.

A systematic review and meta-analysis highlights the safety and efficacy of excimer laser trabeculostomy as an implant-free MIGS procedure for managing open-angle glaucoma and ocular hypertension, either alone or in combination with cataract surgery.

The funding will help further the glaucoma program alongside new board member Carol Gallagher.

The state-of-the-art facility more than doubles the institute’s footprint, enhancing patient care, research, and education.

Direct selective laser trabeculoplasty enhances the experience for both patients and physicians, he notes, while also mitigating issues related to poor adherence and ocular surface disease from topical therapy.

Ying Han, MD, PhD discusses glaucoma management strategies, including transitioning care between ophthalmologists and optometrists, improving diagnosis, and the hope for future glaucoma developments.

SightScore is a saliva test that looks at millions of genetic variants in the patient’s genome to create a personalized polygenic risk score for glaucoma.

The focus in recent years has shifted to reducing the long-term burden of medical therapy, minimizing the risk of medication toxicity and persistent ocular surface disease.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

At the Envision Summit 2025 in San Juan, Puerto Rico, Rachel Simpson, MD, talked about new developments in glaucoma treatment and really how to tailor glaucoma treatment to the patient.

At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.

Yvonne Ou, MD, a professor of ophthalmology at the University of California San Francisco, spoke about lifestyle modifications for glaucoma at this year's Glaucoma 360 meeting.

The 2 phase II trials, Osprey and Apteryx successfully met all primary and secondary endpoints.

M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, California. This lecture was entitled, "Rethinking Race as a Risk Factor for Glaucoma: What Really Matters?"

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her research can align with human glaucoma research to move the entire field

Sunita Radhakrishnan, MD, shares insights on the use of electric neurostimulation and its potential use in the treatment of glaucoma, as evidenced by its current use in Europe and the upcoming trials for use in the US.

Patients’ near visual needs is important when prescribing medications for glaucoma treatment

Real-world scenarios showcase a shift in treatment paradigms

Through its ophthalmic program, Mercy Ships provides critical eye surgeries and trains local professionals, ensuring sustainable eye care for the future.

Recipients will be awarded $100,000 to support a collaborative project related to glaucoma

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.